Free Trial
NASDAQ:AVXL

Anavex Life Sciences Q2 2023 Earnings Report

Anavex Life Sciences logo
$10.98 -0.08 (-0.72%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$11.01 +0.03 (+0.27%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anavex Life Sciences EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anavex Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anavex Life Sciences Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Tuesday, May 9, 2023
Conference Call Time
8:30AM ET

Upcoming Earnings

Anavex Life Sciences' Q3 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Anavex Life Sciences Earnings Headlines

Anavex Life Sciences files $300M common stock offering
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Anavex Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email.

About Anavex Life Sciences

Anavex Life Sciences (NASDAQ:AVXL) (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics targeting neurodegenerative and neurodevelopmental disorders. Founded in 2004 and headquartered in New York, with research facilities in Europe and North America, Anavex focuses on leveraging its sigma-1 receptor drug development platform. This platform aims to modulate cell stress and restore cellular homeostasis in diseases characterized by protein misfolding, oxidative stress and mitochondrial dysfunction.

The company’s lead asset, ANAVEX2-73 (blarcamesine), is being investigated in multiple clinical trials for the treatment of Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome. Anavex also pursues earlier stage opportunities, including ANAVEX3-71 for epilepsy and anxiety disorders, and exploratory compounds aimed at amyotrophic lateral sclerosis (ALS) and other central nervous system indications. Regulatory interactions to expedite development pathways, such as Fast Track designation in the United States, support the company’s clinical strategy.

Anavex collaborates with academic institutions and contract research organizations across the United States, Europe and Australia to conduct its preclinical and clinical research programs. These partnerships facilitate access to specialized trial sites and advanced biomarker techniques. The company’s global presence enables it to recruit diverse patient populations and engage with key opinion leaders in neurology, psychiatry and rare disease communities.

Under the leadership of President and CEO Christopher U. Missling, PhD, Anavex emphasizes a translational medicine approach, integrating molecular science with clinical development. The management team combines expertise in neuroscience, regulatory affairs and biopharmaceutical commercialization, positioning the company to advance its pipeline efficiently. Anavex Life Sciences continues to explore strategic collaborations and licensing arrangements to broaden its R&D capabilities and maximize potential patient impact.

View Anavex Life Sciences Profile

More Earnings Resources from MarketBeat